# Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

> **NCT00002800** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Neutropenia

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** lintuzumab
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** idarubicin

## Key facts

- **NCT ID:** NCT00002800
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002800, "Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00002800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*